Randomized Trialvery high evidence
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
The New England journal of medicine·September 29, 2026·PMID 42814954
Why it mattersObesity often coexists with knee osteoarthritis and obstructive sleep apnea, and effective weight loss can improve both. Retatrutide's triple-agonist mechanism may offer greater weight reduction than existing incretin therapies, with meaningful benefits on pain and sleep apnea.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled